

# Intravenous Immunoglobulin (IVIG) Market in United States - 2022 Edition

<https://marketpublishers.com/r/I2F0F9A9554FEN.html>

Date: November 2022

Pages: 76

Price: US\$ 2,200.00 (Single User License)

ID: I2F0F9A9554FEN

## Abstracts

Intravenous Immunoglobulin (IVIG) is a therapy treatment for patients with antibody deficiencies. It is prepared from a pool of immunoglobulins (antibodies) from the plasma of thousands of healthy donors. Immunoglobulins are made by the immune system of healthy people for the purpose of fighting infections. The intravenous immunoglobulin in United States market is expected to increase by USD 2.5 billion, at a compound annual growth rate (CAGR) of 6.4% from 2022 to 2028, according to the latest edition of the Intravenous Immunoglobulin Market in United States Report.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into intravenous immunoglobulin market in United States. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the intravenous immunoglobulin industry.

This industry report offers market estimates and forecasts of the United States market, followed by a detailed analysis of the application, and end user. The United States market for intravenous immunoglobulin can be segmented by application: chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, others. The immunodeficiency diseases segment held the largest revenue share in 2021. Intravenous immunoglobulin market is further segmented by end user: homecare, hospitals & clinics.

By application:

chronic inflammatory demyelinating polyneuropathy (CIDP)

chronic lymphocytic leukemia

congenital HIV/AIDS

guillain-barre syndrome (GBS)

hypogammaglobulinemia

immune thrombocytopenic purpura (ITP)

immunodeficiency diseases

kawasaki disease

multifocal motor neuropathy (MMN)

myasthenia gravis

others

By end user:

homecare

hospitals & clinics

The market research report covers the analysis of key stake holders of the intravenous immunoglobulin market in United States. Some of the leading players profiled in the report include ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols, S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, among others.

**\*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES**

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

### Scope of the Report

To analyze and forecast the market size of the intravenous immunoglobulin market in United States.

To classify and forecast the intravenous immunoglobulin market in United States based on application, end user.

To identify drivers and challenges for the intravenous immunoglobulin market in United States.

To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the intravenous immunoglobulin market in United States.

To identify and analyze the profile of leading players operating in the intravenous immunoglobulin market in United States.

### Why Choose This Report

Gain a reliable outlook of the intravenous immunoglobulin market in United States forecasts from 2022 to 2028 across scenarios.

Identify growth segments for investment.

Stay ahead of competitors through company profiles and market data.

The market estimate for ease of analysis across scenarios in Excel format.

Strategy consulting and research support for three months.

Print authentication provided for the single-user license.

## Contents

### **PART 1. INTRODUCTION**

Report description  
Objectives of the study  
Market segment  
Years considered for the report  
Currency  
Key target audience

### **PART 2. METHODOLOGY**

### **PART 3. EXECUTIVE SUMMARY**

### **PART 4. MARKET OVERVIEW**

Introduction  
Drivers  
Restraints  
Impact of COVID-19 pandemic

### **PART 5. MARKET BREAKDOWN BY APPLICATION**

Chronic inflammatory demyelinating polyneuropathy (CIDP)  
Chronic lymphocytic leukemia  
Congenital HIV/AIDS  
Guillain-barre syndrome (GBS)  
Hypogammaglobulinemia  
Immune thrombocytopenic purpura (ITP)  
Immunodeficiency diseases  
Kawasaki disease  
Multifocal motor neuropathy (MMN)  
Myasthenia gravis  
Others

### **PART 6. MARKET BREAKDOWN BY END USER**

Homecare

Hospitals & clinics

## **PART 7. KEY COMPANIES**

ADMA Biologics Inc.

Biotest AG

CSL Limited

Grifols, S.A.

Johnson & Johnson

Kedrion Biopharma Inc. (Kedrion SpA)

LFB S.A.

Octapharma AG

Takeda Pharmaceutical Company Limited

**\*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES**

**DISCLAIMER**

## I would like to order

Product name: Intravenous Immunoglobulin (IVIG) Market in United States - 2022 Edition

Product link: <https://marketpublishers.com/r/l2F0F9A9554FEN.html>

Price: US\$ 2,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l2F0F9A9554FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970